ender diagnostics and SWISS collaborate to test cabin crew for COVID-19
ender diagnostics, a Swiss company specializing in the development of rapid molecular biological tests, today announced a collaboration with Swiss International Air Lines (SWISS), a subsidiary of Lufthansa AG, to test all long-haul cabin crew members for SARS-CoV-2, the virus which causes COVID-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200906005019/en/
Swiss Airlines COVID-19 Test Center (Photo: Business Wire)
Constant rapid and flexible testing is the key to controlling the coronavirus pandemic. Testing SWISS long-haul crew members prior to departure working with ender diagnostics will help to further improve detection of COVID-19 infection, increasing the safety and confidence of people traveling.
Martin Knuchel, Head of Crisis, Emergency & Business Continuity Management Lufthansa Group Airlines and Pandemic Coordinator, commented: «The safety and confidence of our passengers and employees is paramount for SWISS. The decision to adopt the fast, innovative and easy-to-use testing solutions developed by ender diagnostics further underlines our absolute commitment to make air travel as safe as possible.»
ender diagnostics specializes in isothermal PCR*-based test kits for laboratory and on-site diagnosis. It has launched two CE-marked tests in Europe: ender LAB in June and ender MASS in August 2020. The ender LAB test allows laboratories to directly detect SARS-CoV-2 on standard real-time PCR devices within 30 minutes of extraction of the viral RNA. This is significantly faster than commercially available PCR tests, which take several hours. ender MASS offers additional benefits by enabling detection in a simplified process, considerably reducing the workload for medical professionals and laboratories. It is designed to enable on-site and pop-up labs to operate rapid testing in diverse settings, including travel-related locations such as airports and cruise ships.
Hans-Peter Frank, Chief Business Officer of ender diagnostics, said: «With simplified workflows and analysis, our products can process up to eight times as many tests as conventional PCR test over the same period. This significantly increases both test capacity and flexibility in laboratories and is a promising step towards mass screening. We are pleased to be able to support SWISS in their efforts to protect their passengers and employees.»
About ender diagnostics
ender diagnostics is a private company headquartered in Bern, Switzerland, and with US offices in Miami. ender diagnostics focuses on the development of rapid molecular tests for the detection of SARS-CoV-2. The ender team has extensive experience in developing molecular biological rapid tests for infectious diseases. The company is supported by several private investors with know-how and financing. https://enderdiagnostics.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200906005019/en/
Contact information
For media inquiries, please contact:
media@enderdiagnostics.com
For more information about ender diagnostics’ products, please contact:
info@enderdiagnostics.com
Hans-Peter Frank
Chief Business Officer
hp.frank@enderdiagnostics.com
+41 79 743 27 77
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
Thales Powers CES*-Winning Post-Quantum Chip From Samsung Electronics7.1.2026 09:15:00 EET | Press release
Quantum computers, with their unprecedented processing power, will ultimately challenge today’s encryption standards. This is why Thales welcomes the CES 2026 recognition awarded to the new post-quantum–ready security chip from Samsung Electronics' System LSI Business, which embeds Thales’ secure operating system and quantum-resistant cryptographic libraries. This breakthrough represents a major step forward in protecting connected devices against both current cyberattacks and tomorrow’s quantum-era threats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106145232/en/ Thales’ hardened OS enables Samsung's award-winning security chip to deliver hardware-based, quantum-resistant protection from the moment devices power on. Ultimately, it ensures that encrypted data and device credentials remain secure against both classical and quantum attacks, preserving confidentiality, integrity and long-term trust, even in a post-quantu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom